Contract research organization Inotiv announced a partnership with Lithuanian multiomics analytics firm Vugene to integrate AI‑enabled bioinformatics into early drug discovery workflows. Under the deal, Inotiv will access Vugene’s platform to analyze genomics, transcriptomics, proteomics and metabolomics datasets to improve target selection and preclinical predictions of efficacy and safety. Inotiv framed the collaboration as a move to accelerate data‑driven decisions for clients and reduce attrition in translational research.